Menu
Three drugmakers recently announced refunds to 340B covered entities, while two others announced NDC changes.

Lilly, Indivior, Kedrion to Refund 340B Covered Entities for Overcharges, Others Announce NDC Changes

Shannon Young, Associate Editor/Senior Writer Views
Three drugmakers are offering refunds to 340B covered entities that purchased certain drugs between 2022 and 2025 following recalculations of [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.

« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live